Engflag

Dozone

Quick links to important sections

Dozone

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dozone

Quick Facts

Property Description
Active ingredient Doxazosin (as the Mesilate salt)
Form Tablet (Immediate Release and Extended Release)
Pharmacological class Selective Alpha-Adrenergic Blocking Agent (α-blocker)
Common purpose Reduction of systemic vascular resistance and smooth muscle relaxation
Origin Synthetic (Quinazoline Derivative)

What is Doxazosin and What Type of Drug is It?

Doxazosin is a synthetic compound classified as a Selective Alpha-Adrenergic Blocking Agent, or alpha-blocker, used to influence vascular and smooth muscle tone. The medication is chemically defined as a quinazoline derivative. This pharmacological identity places it within a group of drugs that specifically target and block the alpha-1-adrenoceptors on postsynaptic tissues. Doxazosin exerts its therapeutic effect by reducing total peripheral resistance through this selective postsynaptic alpha1-blockade. The active compound is typically prepared as the salt Doxazosin Mesilate to optimize pharmaceutical stability and bioavailability.

Composition, Origin, and Available Forms

The active ingredient, Doxazosin Mesilate, is a single-ingredient compound derived entirely through synthetic processes and is prepared exclusively for oral administration. While Dozone is one brand name for this compound, the drug is also sold under other trade names, such as Cardura. The medication is consistently supplied as a solid oral dosage form, available as both standard Immediate Release (IR) tablets and Extended Release (ER) tablets. The availability of the ER formulation is a key differentiating feature, as its controlled-release mechanism is designed to provide a smoother, more sustained therapeutic concentration compared to the IR formulation.

The General Purpose of Alpha-1 Blockade

The general purpose of Doxazosin's pharmacological action is to reduce overall systemic vascular resistance and relieve smooth muscle tension in key areas of the body. By preventing naturally occurring signaling agents from binding to the alpha1-adrenoceptors, the medication induces vasodilation in the circulatory system. This mechanism is clinically recognized for its effectiveness in lessening the pressure exerted on arterial walls. Additionally, Doxazosin Mesilate selectively antagonizes alpha1-adrenergic receptors in the smooth muscle of the bladder neck and prostate, leading to smooth muscle relaxation. This structural effect is generally used to facilitate improvements in certain aspects of urinary flow, which is a typical neutral use scenario for the drug.

Regulatory References

  1. Doxazosin Mesylate Labeling Information

What side effects are possible with Dozone?

Possible Side Effects and Safety Information

Doxazosin's safety profile is defined by officially documented adverse reactions classified by frequency and body system, primarily reflecting its function as an alpha-1 adrenoceptor blocker.

Adverse Reaction Scope

The most frequently reported (classified as Common in regulatory documents) adverse effects are those linked to the drug's vasodilatory action, including dizziness, headache, fatigue, asthenia (weakness), and postural hypotension (a drop in blood pressure upon standing). Other common reports involve the respiratory system (e.g., rhinitis, dyspnoea) and general conditions like peripheral oedema (swelling of extremities).

Reactions classified as Uncommon to Very Rare involve various systems, including the nervous system (syncope, tremor), gastrointestinal system (vomiting, flatulence), and hepato-biliary system (e.g., cholestasis, hepatitis).

Serious Safety Considerations

The official labeling documents rare but clinically significant adverse reactions and warnings:

  • Syncope and Postural Hypotension: The potential for a sudden, symptomatic drop in blood pressure, which may lead to syncope (loss of consciousness), is noted, especially upon the commencement of therapy or after an increase in dosage strength.
  • Priapism: A prolonged, painful, and unwanted erection has been reported with alpha-1 blockers and requires immediate medical attention.
  • Intraoperative Floppy Iris Syndrome (IFIS): A risk during cataract surgery for patients who are currently taking or have previously taken Doxazosin, necessitating surgical precautions.

Safety Restrictions and Special Populations

Use is subject to specific regulatory constraints:

  • Hepatic Impairment: Doxazosin is not recommended for use in patients with severe hepatic impairment due to a lack of clinical experience. Caution is advised for those with mild to moderate impairment.
  • Contraindications: The medicine is contraindicated in patients with known hypersensitivity to Doxazosin or other quinazoline derivatives, and as monotherapy in patients with conditions like overflow bladder or anuria.
  • Pediatric Use: Safety and effectiveness have not been established in individuals under 18 years of age, and use is not recommended in this population.

These classifications structure the official safety profile by defining the probability of known effects and establishing clear limitations on use for specific patient groups.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented symptoms and required actions for a Doxazosin (Dozone) overdose, based on governmental regulatory prescribing information.

Documented Overdose Manifestations

The primary and most serious documented consequence of a Doxazosin overdose is profound hypotension (extremely low blood pressure), resulting from the drug's exaggerated alpha-blocking effect. Other manifestations reported in regulatory documents include drowsiness and changes in heart rate, such as reflex tachycardia.

Required Emergency Actions

An overdose is considered a medical emergency. Regulatory authorities mandate that individuals must seek immediate medical attention by contacting emergency services or a Poison Control center if an overdose is suspected or if severe symptoms, such as significant lightheadedness or fainting due to hypotension, occur.

Management and Monitoring

Overdose treatment is entirely symptomatic and supportive, as there is no specific antidote officially documented. To manage profound hypotension, initial steps include placing the patient in a supine position. If this is insufficient, the use of vasopressors may be considered, along with measures to remove unabsorbed drug from the gastrointestinal tract. Continuous close monitoring of vital signs is required throughout the management process.

Therapeutic Uses of Dozone

Therapeutic Indications and Clinical Uses

Dozone is a corticosteroid medication primarily utilized for its potent anti-inflammatory and immunosuppressive properties. It is indicated for the management of a wide range of conditions where the reduction of inflammation and the suppression of an overactive immune system are required.

Inflammatory and Autoimmune Conditions

The medication is frequently prescribed to treat systemic inflammatory disorders. These include:

  • Rheumatoid Arthritis: To manage acute exacerbations and reduce joint inflammation and pain.
  • Systemic Lupus Erythematosus (SLE): To address various systemic manifestations of the disease.
  • Psoriatic Arthritis and Osteoarthritis: To alleviate severe inflammation during acute episodes.

Allergic Reactions and Respiratory Disorders

Dozone is effective in managing severe or incapacitating allergic conditions that do not respond to conventional treatments. Key applications include:

  • Bronchial Asthma: To reduce airway inflammation during acute or chronic phases.
  • Allergic Rhinitis and Contact Dermatitis: For the control of severe inflammatory skin and mucosal reactions.
  • Drug Hypersensitivity Reactions: To mitigate systemic allergic responses to medications.

Dermatological Diseases

Several inflammatory skin conditions are managed with this medication, particularly those that are systemic or resistant to topical therapies:

  • Pemphigus and Bullous Dermatitis Herpetiformis: To control blistering and skin erosion.
  • Severe Erythema Multiforme (Stevens-Johnson syndrome): As part of a broader therapeutic approach to manage systemic inflammation.
  • Exfoliative Dermatitis: To reduce widespread skin redness and scaling.

Hematological and Neoplastic Disorders

In hematology and oncology, Dozone serves as an adjunctive or primary treatment for various blood-related and cancerous conditions:

  • Immune Thrombocytopenic Purpura (ITP): To increase platelet counts by reducing immune-mediated destruction.
  • Autoimmune Hemolytic Anemia: To suppress the immune system's attack on red blood cells.
  • Leukemia and Lymphoma: Used in palliative management or as part of specific chemotherapy protocols to suppress malignant cell growth and manage associated inflammation.

Endocrine and Other Applications

Dozone is also utilized in the management of endocrine disorders, such as primary or secondary adrenocortical insufficiency, where it acts as a replacement for natural glucocorticoids. Additionally, it may be used to treat inflammatory conditions of the eyes, gastrointestinal tract (such as ulcerative colitis), and the renal system (such as nephrotic syndrome) to induce remission or reduce protein excretion.

Regulatory References

  1. NIH DailyMed Prescribing Information

Eligibility and Restrictions for Use

Official Population Eligibility Profile (Based on Regulatory Labels)

This section outlines who can and cannot use Dapsone (Dozone) based strictly on authoritative government regulatory documents, such as those from the FDA and EMA.

Absolute Non-Eligibility (Contraindications)

Population/Condition Restriction
Hypersensitivity Must not be used in individuals with a known allergy to Dapsone or any of its inactive ingredients.
Severe Anemia Contraindicated in certain regions (e.g., EU/UK); should be treated prior to initiating therapy (US).
Severe G6PD Deficiency Contraindicated in certain regions; requires extreme caution in all patients with the deficiency.

Restricted or Conditional Use

  • Genetic Enzyme Deficiencies: Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency or Methemoglobin Reductase Deficiency are at higher risk of hemolytic effects and require close monitoring and caution in use.
  • Liver Impairment: Requires caution and monitoring of liver function (LFTs) due to the risk of toxic hepatitis. Discontinuation is required if sustained abnormalities are present.
  • Pregnancy and Breastfeeding: Use during pregnancy should occur only if clearly needed (Category C). Dapsone is excreted in breast milk and may cause infant hemolytic anemia, requiring a careful risk-benefit assessment for nursing mothers.
  • Pediatric Use: Generally established; however, use in children under six years old is often listed as not established due to limited data.

What should I know about interactions with other medicines?

Pharmacodynamic Interactions

Co-administration with Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil, vardenafil) is officially documented to result in additive blood pressure lowering effects. This pharmacodynamic interaction increases the risk of symptomatic hypotension. To mitigate this risk, regulatory agencies recommend a 6-hour time interval following the intake of Doxazosin before administering a PDE-5 inhibitor. Concurrent use with other antihypertensive medications, such as beta-blockers or diuretics, may similarly lead to the potentiation of blood pressure lowering activity.

Pharmacokinetic Interactions

Doxazosin is primarily metabolized via the CYP3A4 pathway in the liver. Co-administration with strong CYP3A4 inhibitors, including specific agents like ketoconazole, ritonavir, or clarithromycin, is officially advised against or warrants caution. This pharmacokinetic interaction can lead to increased systemic exposure and higher plasma concentrations of Doxazosin. A related caution exists for other quinazoline derivatives, as hypersensitivity is a formal class-related contraindication.

Other Interactions and Population Notes

Consumption of ethanol (alcohol) is noted to enhance the blood pressure lowering effect, which increases the potential for hypotension. Furthermore, due to the drug’s extensive metabolism, administration requires particular caution in patients with evidence of impaired hepatic function. Use is not recommended in patients with severe hepatic impairment due to a lack of clinical experience in this population.

Mechanism of Action

The physiological effects of Doxazosin are derived from its ability to act as a selective competitive antagonist at the postsynaptic Alpha-1 Adrenoceptor (alpha1-adrenoceptor). This molecular action directly translates into two key mechanistic domains: modulation of vascular smooth muscle tone and smooth muscle contractility in the lower urinary tract.

Modulating Autonomic Control of Systemic Vascular Tone

This domain covers the drug's action on alpha1-receptors located on the smooth muscle of blood vessels. By blocking excitatory signals, Doxazosin initiates a cascade that results in the relaxation and widening of the vasculature (vasodilation). This action contributes to a reduction in the physical resistance of the circulatory system (Systemic Vascular Resistance, SVR).

Functional Modulation of Lower Urinary Tract Smooth Muscle

This mechanism targets the alpha1-receptors specifically found on the smooth muscle in structures like the prostatic capsule and bladder neck. Antagonism at these sites suppresses the sympathetic-driven contractile signals, resulting in the relaxation of the smooth muscle and reduced tension in the bladder outlet.

Sustaining the Mechanistic Effect (ER Formulation)

While the core mechanism is receptor blockade, the Extended Release (ER) formulation employs a delivery system designed to provide a sustained rate of compound release. This mechanism is designed to provide sustained receptor occupancy, thereby supporting a consistent pattern of pharmacodynamic effect over 24 hours.

Dosage and Administration Information

Doxazosin (Dozone) is administered via the oral route and is available as either an Immediate Release (IR) tablet or an Extended Release (ER) tablet. The dosing regimen is determined by the specific dosage form and the clinical indication. For chronic hypertension, the IR tablet is initiated at 1 mg once daily, and the dose can be adjusted up to a maximum of 16 mg once daily. For benign prostatic hyperplasia (BPH), the IR form also starts at 1 mg (maximum 8 mg), while the ER form has a starting dose of 4 mg, with a maximum of 8 mg once daily.

All forms are intended for a once-daily schedule. A key administration constraint is that the ER tablet must be swallowed whole and must not be cut, crushed, or chewed to preserve the release mechanism. The ER tablet is taken with breakfast, whereas the IR tablet can be taken irrespective of food intake. Dose adjustments, known as titration, are typically spaced by 1–2 weeks for the IR form and 3–4 weeks for the ER form.

The usual adult dosage applies to older adults and individuals with renal impairment, while efficacy has not been established for the pediatric population. If use is discontinued for several days, the standard procedure is to restart the regimen at the initial 1 mg (IR) or 4 mg (ER) dose and begin the titration process again.

Recent Clinical Evidence

Evidence for Use in Managing Symptoms of Benign Prostatic Hyperplasia (BPH)

The research exploring doxazosin for the symptoms associated with BPH has been evaluated in primary research, mainly Randomized Controlled Trials (RCTs). These short-term studies, often compared to placebo, were used in research exploring how symptoms change over time in men with moderate-to-severe symptoms. The research mainly examined patient-reported outcomes describing perceived discomfort (symptom scores) and functional measures like the maximum urinary flow rate. Studies reported measurements of change in symptom scores and observed change in urinary flow rates within the studied populations over the short term.

Evidence for Use in the Management of Chronic High Blood Pressure (Hypertension)

Doxazosin was also studied for its potential to influence systemic pressure. This evidence comes from short-term RCTs and large, multi-year Cardiovascular Outcome Trials. Short-term research highlights dose-dependent patterns related to measured change in blood pressure. However, a major outcome trial (ALLHAT) indicated that doxazosin was associated with a higher rate of congestive heart failure and stroke compared to another treatment arm, leading to the early discontinuation of the doxazosin component of that study.

Long-Term Studies and Research Gaps

Long-term open-label extension studies for BPH followed patients for up to four years, contributing to understanding symptom patterns over intermediate periods, but there is limited information for long-term outcomes regarding the absolute prevention of major BPH events. The comparative evidence from the large-scale hypertension trials indicates that its role as a primary monotherapy is uncertain due to observed risk patterns. Furthermore, the results apply only to the populations studied, and the long-term effects are not fully established concerning the durability of functional improvements or the full clinical significance of metabolic changes observed in trials.

Key Studies & References

  1. Doxazosin Mesylate Official Prescribing Information and Label (DailyMed - NIH)

Frequently Asked Questions (FAQ)

Common questions about Dozone (FAQ)

Q: What is the maximum daily dose for the ER (Extended Release) tablet when treating BPH?

Official prescribing information defines the upper dose limit for the extended-release formulation when used to treat benign prostatic hyperplasia (BPH). This maximum is systematically defined in regulatory documents to guide the dosing regimen.

Q: What should I do if I forget to take my Doxazosin dose for several days?

Official prescribing information outlines the standard protocol regarding missed doses, which is detailed in the patient information leaflet. This protocol generally involves a defined approach based on the time elapsed since the missed dose and specifically advises against taking extra doses to make up for a missed one.

Q: How does Doxazosin interact with alcohol?

Regulatory warnings state that alcohol consumption may enhance the hypotensive effect of Doxazosin. This means the combination has the potential to increase the risk of experiencing symptomatic low blood pressure, specifically postural hypotension.

Q: What are the most common side effects of Doxazosin?

According to official regulatory documents, the most commonly reported adverse reactions in clinical trials were dizziness and symptoms related to feeling generally unwell, such as fatigue and malaise. These effects are commonly reported in regulatory documents describing the drug’s safety profile.

Q: How often is the dose adjusted (titration) for the Immediate Release (IR) formulation?

The systematic dosage regimen for the immediate-release formulation, known as titration, outlines that dose adjustments are typically spaced by 1 to 2 weeks. This defined frequency is part of the established procedure for slowly increasing the medication.

Q: What precautions are needed when taking Doxazosin with other CYP3A4-inhibiting drugs?

Doxazosin is primarily processed in the body by the CYP3A4 liver enzyme. Regulatory information notes that co-administration with strong CYP3A4 inhibitors (like certain antifungals) may increase the body's exposure to Doxazosin. This increased exposure is noted in regulatory documents as potentially increasing the risk of experiencing symptomatic hypotension.

Q: Can Doxazosin cause weight gain?

Official safety data lists peripheral oedema, or swelling of the extremities, as a common side effect of Doxazosin. This condition is related to fluid retention and is a common finding noted in clinical safety reviews of the medication.

Q: Is it necessary to monitor blood pressure while on Doxazosin?

The potential for postural hypotension (a drop in blood pressure when changing posture) is highlighted in official safety warnings. Therefore, official safety information highlights the importance of awareness regarding symptoms related to a drop in blood pressure.

Q: What is the chemical name and structure of the Doxazosin molecule?

The chemical name is purely factual information found in the official description of the drug. The active ingredient, Doxazosin mesylate, is a quinazoline derivative whose full chemical name is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate.

How should Dozone be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory information provides specific guidance for storing and disposing of Dozone to maintain its integrity and ensure safety. These requirements are strictly based on governmental documentation.

Requirement Type Official Guidance
Temperature Store below 30 C (86°F).
Environmental Protection Store in a cool, dry place. Protect from direct sunlight, moisture, and heat.
Container Keep the medicine in a tightly closed container.
Child Safety Keep out of the reach of children and pets.
Disposal Discard any unused medicine properly. Do not flush it in the toilet or throw it into the drain.

Adherence to these conditions helps ensure the product's stability until its expiration date. Medicines must not be used if expired or damaged.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dozone found in:

A-Z Index: